Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices.

Autor:	Bertges DJ; Division of Vascular Surgery, University of Vermont Medical Center, Burlington, Vermont, USA. Electronic address: daniel.bertges@uvmhealth.org., Eldrup-Jorgensen J; Division of Vascular Surgery, Maine Medical Center, Portland, Maine, USA., Robbins S; Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Ssemaganda H; Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Malone M; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Marinac-Dabic D; Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Smale J; BD Peripheral Intervention, Tempe, Arizona, USA., Lottes AE; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA., Majithia A; Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Resnic FS; Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2021 Dec 13; Vol. 14 (23), pp. 2598-2609.
DOI:	10.1016/j.jcin.2021.08.058
Abstrakt:	Objectives: This study sought to determine the safety and efficacy of paclitaxel (PTX) devices in the treatment of peripheral artery disease involving the femoropopliteal artery. Background: A meta-analysis of PTX devices for the treatment of femoropopliteal artery disease reported a mortality signal. Methods: This was a multicenter cohort study using an integrated clinical data surveillance system to conduct a prospective, propensity score-matched survival analysis of 2,456 patients in the Society for Vascular Surgery Vascular Quality Initiative from January 2017 to May 2020. The study compared PTX drug-coated balloon angioplasty versus percutaneous transluminal balloon angioplasty, PTX drug-eluting stents versus bare-metal stents, and any PTX device versus any non-PTX device. The primary outcome was 2-year survival. Secondary endpoints were successful ambulation and interventional success. Results: Treatment with any PTX device versus any non-PTX device was associated with increased 2-year survival (89.5% vs 86.7%; HR: 0.79; 95% CI: 0.72-0.87; P = 0.004), improved interventional success (81.6% vs 77.6%; HR: 0.82; 95% CI: 0.74-0.91; P < 0.001), and higher rates of independent ambulation at 1 year (86.0% vs 83.4%; HR: 0.85; 95% CI: 0.79-0.91; P = 0.008). Treatment with PTX drug-coated balloon angioplasty was associated with improved survival at 2 years (88.9% vs 85.7%; HR: 0.77; 95% CI: 0.70-0.86; P = 0.005), while PTX drug-eluting stent therapy was associated with similar survival compared with bare-metal stent therapy (91.3% vs 89.6%; HR: 0.84; 95% CI: 0.70-1.01; P = 0.36). Conclusions: In this prospective, active surveillance of a national clinical registry, PTX-containing devices were associated with increased survival at 2 years and improved clinical outcomes at 1 year. (VQI DELTA Paclitaxel Device Safety Analysis [VQI-PTX]; NCT04110288). Competing Interests: Funding Support and Author Disclosures This research was supported through U.S. Food and Drug Administration research grant 1U01FD004963-01: Active Surveillance of Cardiovascular Devices: The Multi-Registry DELTA Network. Mr Smale is an employee of BD Peripheral Intervention. Dr Lottes was an employee of Cook Medical during the conduct of the study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2021 American College of Cardiology Foundation. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu